|Tiziana Life Sc
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Tiziana Life Sc Share Discussion Threads
Showing 251 to 269 of 275 messages
|Nice recent pick up in share price Maybe good news on the way? IMHO|
|Two nice bits of news. Lots of facts and figures but interesting,as doing a quick bit of maths, I've come up with
If the company sells
Worst case scenario £2 a share
Best case £3.50 a share upwards to whatever,the sky is the limit.
All approx but IMO possible.
That is if no more shares are issued. But I think they still have a few million in the bank.|
|Great that the Welsh government is helping with funding.
All we need is a little bit of news on the Milciclib trial, which I know seems to be working, and the fact that part of it is still recruiting patients, to me, is a good sign. And the liver trials. So with all this going on perhaps big pharma will make a bid, who knows. Good luck all, exciting times ahead.|
|Tiziana Life Sciences PLC Partnership with Cardiff Researchers Wins AwardSource: RNS Non-RegulatoryTIDMTILSTiziana Life Sciences PLC01 June 2016Tiziana Life Sciences PLC("Tiziana" or the "Company")Tiziana Partnership with Cardiff Researchers Wins Innovation in Healthcare AwardJune 1, 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today notes that Cardiff University has announced that the partnership between Tiziana Life Sciences and researchers at Cardiff University, which has led to the development of a potential new drug for metastatic breast cancer, has won the Innovation in Healthcare category at Cardiff University's Innovation and Impact Awards 2016.The award winning venture between Tiziana and a joint team from the European Cancer Stem Cell Research Institute and School of Pharmacy and Pharmaceutical Sciences at Cardiff has led to the identification of a small molecule inhibitor of Bcl3, which possesses potent anti-cancer properties for breast and colorectal metastatic cancer.Gabriele Cerrone, Chairman of Tiziana Life Sciences Plc, said: "Work on this project helped us to cement our relationship with Cardiff University and drives forward the new field of cancer stem cell therapeutics. This Award showcases the great work being done at Cardiff to identify inhibitors which can be developed into novel drugs for cancers."The full text of the announcement from Cardiff University is as follows:Innovation in Healthcare: Tiziana Life Sciences PlcA partnership which is developing a new drug for metastatic breast cancer has won the Innovation in Healthcare honour at Cardiff University's Innovation and Impact Awards 2016.The venture, led by a joint team from the European Cancer Stem Cell Research Institute and School of Pharmacy and Pharmaceutical Sciences at Cardiff, combined academic expertise in drug development and cancer biology together with experience of restructuring biotechnology companies.The project originated from a PhD study of mammary gland development in the University's School of Biosciences, where a team in the Clarkson laboratory identified the oncogene Bcl3 as a potential regulator of metastasis.The lab then collaborated with Dr Andrea Brancale and Dr Andrew Westwell of the University's School of Pharmacy and Pharmaceutical Sciences to design and develop a novel inhibitor of Bcl3 for use as an anti-cancer agent.By 2013 the team had identified a small molecule inhibitor of Bcl3, which the Clarkson lab showed to possess potent anti-cancer properties for breast and colorectal metastatic cancer.The team then approached biotech entrepreneur Gabriele Cerrone to discuss commercial investment, and a new biotechnology company - Tiziana Life Sciences Plc - was founded.Launched on the AIM market at the London Stock Exchange in April 2014, it currently has a market capitalization of around GBP150M.Dr Richard Clarkson, Senior Lecturer of cancer research in the School of Biosciences, said: "We are delighted to win this Award, which recognises the team's dedication and hard work in developing this new form of treatment. This is the first novel targeted agent with anti-cancer stem cell properties to be developed from lab bench to bedside in the UK. It is at the forefront of a new era of anti-metastatic agents to be championed in clinical trials - and is the first anti-cancer agent to be identified, developed, verified and due to be clinically tested in Wales, with funding from the UK commercial sector and Welsh government."Gabriele Cerrone, Chairman of Tiziana Life Sciences Plc, said: "Work on this project helped us to cement our relationship with Cardiff University and drives forward the new field of cancer stem cell therapeutics. This Award showcases the great work being done at Cardiff to identify inhibitors which can be developed into novel drugs for cancers."|
|Foralumab is in Phase2.|
|Patient in Milciclib trial reported on there blog that since starting the trial 18weeks ago there has been no tumour grow and doctor told them it's working. They have a CT scan every six weeks and they recently had there 3rd scan.|
|Takes average $1 billion and 12 years to get a drug to market.|
|Tiziana Life Sciences PLC Journal review of anti - CD3 monoclonal antibodiesSource: RNS Non-RegulatoryTIDMTILSTiziana Life Sciences PLC19 May 2016Tiziana Life Sciences PLC("Tiziana" or the "Company")Immunotherapy journal review of anti - CD3 monoclonal antibodies highlights therapeutic potential of Tiziana's foralumabforalumab is the only fully human anti-CD3 monoclonal antibody currently in development for the modulation of autoimmune diseaseMay 19, 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announced that foralumab, was featured in a review article entitled, "Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside" published online ahead of print in peer-reviewed journal, Immunotherapy (see http://www.futuremedicine.com/toc/imt/0/0). This follows the announcement made by the Company on 11 January 2016 that outlined Tiziana's plans to initially evaluate foralumab in two clinical indications; namely, graft vs host disease, and ulcerative colitis, an inflammatory bowel disease.Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Growing industry focus on clinical applications of immunotherapy has also stimulated greatly increased interest in modulation of immune tolerance.The review article, authored by Dr. Howard Weiner, who joined Tiziana's Scientific Advisory Board earlier this year, and Dr. Chantal Kuhn of Harvard Medical School, highlights unique attributes of foralumab that differentiate it from the other anti-CD3 monoclonal antibodies (mAbs) evaluated in the past. In particular, it was noted that foralumab is currently the only fully human anti-CD3 mAb in development and that this should potentially translate into reduced side effects and improve the overall safety profile of foralumab compared to other anti-CD3 mAbs in development, potentially translating to reduce side effects and an improved overall safety profile as compared with murine and other non - human mAbs.The article also summarized studies demonstrating that the oral or nasal administration of an anti-CD3 mAb has significant potential as a novel approach to treat autoimmune and inflammatory diseases such as Non-alcoholic Steatohepatitis (NASH), inflammatory bowel diseases (IBD) and type 1 diabetes.Tiziana Life Sciences is implementing Dr. Weiner's breakthrough research for clinical development of foralumab.Dr. Howard Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston. He pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases.|
|Completing Phase 2 trials of Milciclib and starting trials on liver cancer with Milciclib .
Wow hopefully some good news when data corollated, soon.|
|Nice bounce. Ooo ah Vicar|
|Added a few more on the cheap today|
|Update would be good !|
|About 1% Jpuff|
|Possibly profit taking to take advantage or lock in positions during its breather. Of course we might get Midiclib news Thursday or Friday which could send this rocketing or crashing!|
|I'm holding firm|
|Wave of panic selling. Any ideas?|
|nice action gla.|
|Midiclib news can't be too far away. This had almost halved so although it has to date had a good recovery we are some way off highs. The CLN's from January's fundraising are cashable at £1.50 s0 120p to 135p was a bargain for pi's. When this moves it moves in bounds- of course this applies to down as well as up.|